Bill Ackman

Controversial short-sellers deliver messages that people would rather not hear

Novelist became world’s fourth richest woman after divorce from Jeff Bezos

Research shows investors should also be wary of firms headed by egotistical chiefs

Performance does not persist, as shown by the latest scorecard from S&P Dow Jones Indices

Bill Ackman’s companies agree to split payout to avoid litigation

McCain Foods boss Dirk Van de Put takes over from Irene Rosenfeld

Irish-headquartered pharma group accused of ‘murky alliance’ that boosts the price of drug acquired in Questcor deal

Stocktake: Merrill Lynch research shows it’s time for investors to hold tough

Stocktake: betting the farm is always dumb – whether you make a bundle or lose the lot

Investors are debating the Sanford Bernstein report which warns that the growth of index funds may distort markets, but such concerns are not new

It’s very difficult to beat the stock market as even top fund managers have shown

Iseq rises as stocks on Wall Street and in Europe lifted by energy companies

A look around the world’s stock markets

The relative minnow has more than tripled in value since 2007

The top 20 earned $15 billion last year; the rest of the industry lost $99 billion

Pershing Square Capital increased stake in beleaguered drug group last November but acts to generate tax loss for investors

Farewell to the Brics, morality and the hedge fund manager and exploiting inattention

Investors can be led astray by firms using non-generally accepted accounting principles

Fast-growing company loses CFO Howard Schiller as it looks to address issues with $11bn Salix Pharma acquisition

They are usually discreet, but a new breed of activist short sellers say they are out to expose financial corruption

Proinsias O’Mahony takes a look at the ups and downs of the stock market

Allergan employs about 900 here, most at its manufacturing plant in Westport

Largest M&A deal of 2014 sees off hostile attention from rival Valeant

Investors hold fire until stronger signs of recovery emerge

Nothing to fear but fear itself

Quebec-based pharmaceutical company takes its hostile $50.8 billion bid directly to shareholders

Canadian-based company said Allergan’s refusal to enter talks left it with no option but to go hostile

Increased bid falls short of expectations and stock in both companies falls

Disappointed Valeant expected to raise cash and stock offer to drive through merger of companies with significant overlap of shareholders

Pitching by bankers on tax inversion targets has reached fever pitch

Groups make products for ageing populations

London Briefing: major drug shares in UK soar on talk of mergers, acquisitions and asset swaps

Transactions worth $140bn so far this year include asset swap between Novartis and GlaxoSmithKline

Howard Schultz accuses hedge fund manager Bill Ackman of being a ‘destroyer of companies’

Proinsias O’Mahony's view of the markets

A.G. Lafley brought back to rekindle growth at world’s largest consumer product maker

Former partner accused of passing confidential information about clients to an alleged inside trader